Biocept Stock

Biocept FCF Yield

Delisted

The Free Cash Flow Yield of Biocept (BIOC) as of Sep 5, 2026 is -295.21 %. In the previous year, Free Cash Flow Yield was 44.36 % — a change of -765.53% (lower).

FCF Yield

-295.21 %

YoY

-765.53%

Last updated:

Free Cash Flow Yield of Biocept is 2026 -295.21 % . Free Cash Flow Yield of Biocept was 2025 44.36 % . It decreases by -765.53% lower compared to the previous year.

The Biocept FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2015
-320.84 USD
Jan 1, 2016
-338.83 USD
Jan 1, 2017
-440.86 USD
Jan 1, 2018
-471.22 USD
Jan 1, 2019
-498.11 USD
Jan 1, 2020
-432.55 USD
Jan 1, 2021
44.36 USD
Jan 1, 2022
-295.21 USD
The Biocept FCF Yield history
YEARFCF YieldYoY
-295.21 %-765.53%
44.36 %-110.25%
-432.55 %-13.16%
-498.11 %+5.71%
-471.22 %+6.89%
-440.86 %+30.11%
-338.83 %+5.61%
-320.84 %+2.13%
-314.14 %
Access this data via the Eulerpool API

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Free Cash Flow Yield of Biocept is -295.21 % in 2026.

Free Cash Flow Yield of Biocept changed from 44.36 % to -295.21 %, representing a -765.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Biocept since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Biocept with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Biocept

All Key Metrics — Biocept